Veralto Corporation (VLTO), a bio-tech firm recently in a spin-off from Danaher and now a public entity, anticipates bolstering its presence in the market quarters. The company posted promising Q1 and Q2 results aligning with analyst projections. Insiders seemingly responded to this growth, with significant stock selling from CEO, Jennifer Honeycutt, and executive Surekha Trivedi. Veralto demonstrated financial stability with sensible debt usage and reported robust free cash flow. EPS forecasts and stock value remain generally positive among Wall Street firms such as UBS keeping a neutral recommendation. Mn Services Vermogensbeheer B.V. and North Star Asset Management Inc. liquidated some shares, while Candriam S.C.A. and Graypoint LLC increased their stakes. Veralto welcomed Vijay Sankaran on the Board of directors, suggesting a likely fresh strategic direction. Notably, Veralto was positioned for inclusion in the prestigious S&P 500.
Veralto Corporation VLTO News Analytics from Wed, 08 Feb 2023 08:00:00 GMT to Sun, 08 Sep 2024 15:13:18 GMT - Rating 8 - Innovation 6 - Information 9 - Rumor -3
